Abstract:Non-small cell lung cancer (NSCLC) is the leading cause of cancer-related deaths worldwide. Despite recent advances, high rates of recurrence highlight the need for novel treatment options. Groundbreaking discoveries in identifying and exploiting the PD-1/PD-L1 (Programmed Death 1/Programmed Death Ligand 1) immune checkpoint have resulted in the approval of monoclonal antibodies that disrupt this interaction as a first-line therapy for lung cancer patients. However, only ~20% of NSCLC patients benefit from checkpoint blockade. A critical question remains as to what mechanisms facilitate resistance to PD-1/PD-L1 therapy and whether other immune checkpoints or pathways can be pursued clinically in combination with this therapy. The integrated stress response (ISR) pathway represents an emerging therapeutic vulnerability. The ISR is a generalized response to maintain cellular homeostasis, and is known to be activated by hypoxia, heme deprivation, amino acid starvation, and oncogenic activation. We previously demonstrated that ISR activation potently induces PD-L1 in NSCLC and suppression of anti-tumor immunity (Suresh et al, Nature Cancer, 2020). We discovered that ISR pathway activation enhances PD-L1 translation through the bypass of inhibitory upstream open reading frames (uORFs) in the PD-L1 5' UTR and a mechanistic link to the translation initiation factor eIF5B. Our latest studies demonstrate that the immune checkpoint protein, CD155 (Cluster of Differentiation 155), is induced by ISR activation. We find that both PD-L1 and CD155 are induced by multiple arms of the ISR pathway, and CD155 harbors inhibitory uORFs in its 5' UTR. Importantly, we observed a significant correlation between PD-L1 and CD155 expression in a panel of primary human lung adenocarcinomas. We further demonstrated that ISR activation inhibits T cell function in vitro and promotes tumor growth in the CMT167 syngeneic mouse model. Analysis of immune cell infiltration using mass cytometry in this in vivo model is ongoing. Currently, we are determining the extent to which ISR inhibition suppresses tumorigenesis by promoting anti-tumor immunity and whether this may synergize with existing immune checkpoint therapies. Overall, these studies will set the stage for determining whether inhibition of the ISR pathway alone or in combination with immune checkpoint blockade will benefit lung cancer patients. Our studies may also lead to new therapeutic approaches to trigger anti-cancer immune responses and improve current strategies. Citation Format: Shayna Elizabeth Thomas-Jardin, Shruthy Suresh, Cheryl Lewis, Chul Ahn, Bret M. Evers, John D. Minna, Kathryn A. O'Donnell. Coordinated regulation of critical immune checkpoint proteins by the integrated stress response (ISR) pathway in lung cancer [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2024; Part 1 (Regular s); 2024 Apr 5-10; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2024;84(6_Suppl) nr 7528.

Figure S1 from Adaptive Protein Translation by the Integrated Stress Response Maintains the Proliferative and Migratory Capacity of Lung Adenocarcinoma Cells

Figure S2 from Adaptive Protein Translation by the Integrated Stress Response Maintains the Proliferative and Migratory Capacity of Lung Adenocarcinoma Cells

Figure S4 from Adaptive Protein Translation by the Integrated Stress Response Maintains the Proliferative and Migratory Capacity of Lung Adenocarcinoma Cells

Supplementary Table 3 from Adaptive Protein Translation by the Integrated Stress Response Maintains the Proliferative and Migratory Capacity of Lung Adenocarcinoma Cells

Abstract 7528: Coordinated regulation of critical immune checkpoint proteins by the integrated stress response (ISR) pathway in lung cancer

Supplementary Figure 1 from EIF4A3 Acts on the PI3K–AKT–ERK1/2–P70S6K Pathway Through FLOT1 to Influence the Development of Lung Adenocarcinoma

Coordinated translational control of multiple immune checkpoints by the integrated stress response pathway in lung cancer

RASGRP2 is a potential immune-related biomarker and regulates mitochondrial-dependent apoptosis in lung adenocarcinoma

Figure S3 from Targeting the IRE1α/XBP1 Endoplasmic Reticulum Stress Response Pathway in &Lt;i>arid1a</i>-Mutant Ovarian Cancers

Supplementary Materials and Methods from Adaptive Protein Translation by the Integrated Stress Response Maintains the Proliferative and Migratory Capacity of Lung Adenocarcinoma Cells

Figure S14 from <i>in Vivo</i> Epigenetic CRISPR Screen Identifies <i>asf1a</i> As an Immunotherapeutic Target in &Lt;i>kras</i>-Mutant Lung Adenocarcinoma

Figure S1 from Targeting the IRE1α/XBP1 Endoplasmic Reticulum Stress Response Pathway in &Lt;i>arid1a</i>-Mutant Ovarian Cancers

Sustaining the Activation of EGFR Signal by Inflammatory Cytokine IL17A Prompts Cell Proliferation and EGFR-TKI Resistance in Lung Cancer

Comprehensive Analysis Uncovers Prognostic and Immunogenic Characteristics of Cellular Senescence for Lung Adenocarcinoma

Identification of an inflammatory response signature associated with prognostic stratification and drug sensitivity in lung adenocarcinoma

Deciphering the prognostic role of endoplasmic reticulum stress in lung adenocarcinoma: integrating prognostic prediction and immunotherapy strategies

U2AF1 S34F enhances tumorigenic potential of lung cells by exhibiting synergy with KRAS mutation and altering response to environmental stress

Adeno-to-squamous transition drives resistance to KRAS inhibition in LKB1 mutant lung cancer

Figure S15 from in Vivo Epigenetic CRISPR Screen Identifies Asf1a As an Immunotherapeutic Target in Kras-Mutant Lung Adenocarcinoma

Figure S16 from <i>in Vivo</i> Epigenetic CRISPR Screen Identifies <i>asf1a</i> As an Immunotherapeutic Target in &Lt;i>kras</i>-Mutant Lung Adenocarcinoma

Abstract 2151: Identification and proteogenomic characterization of novel lung adenocarcinoma subtypes with therapeutic relevance